The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 501–600 of 1,043
Pornnoppadol, G., Bond, L. G., Lucas, M. J., Zupancic, J. M., Kuo, Y.-H., Zhang, B., Greineder, C. F., & Tessier, P. M. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.09.008 · Cited by 62
Designer protein disaggregases to counter neurodegenerative disease
Shorter, J. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.01.008 · Cited by 78
Jakubowski, J. M., Orr, A. A., Le, D. A., & Tamamis, P. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00561 · Cited by 75
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
“Aducanumab, a MAb recently approved by the FDA, seems to be confined to the brain blood volume (Pardridge, 2019), but it can reduce Aβ plaques in AD (Sevigny et al., 2016), probably due to BBB disruption.”
Backgroundde Oliveira, T. R., Erbereli, C. R., Manzine, P. R., Magalhães, T. N. C., Balthazar, M. L. F., Cominetti, M. R., & Faria, R. C. (2020) · ACS Sensors · doi:10.1021/acssensors.9b02463 · Cited by 77
Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
VandeVrede, L., Gibbs, D. M., Koestler, M., La Joie, R., Ljubenkov, P. A., Provost, K., Soleimani‐Meigooni, D., Strom, A., Tsoy, E., Rabinovici, G. D., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12101 · Cited by 70
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 78
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
van der Schaar, J., Visser, L. N. C., Bouwman, F. H., Ket, J. C. F., Scheltens, P., Bredenoord, A. L., & van der Flier, W. M. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00971-3 · Cited by 83
“This becomes especially relevant in light of the development of low-cost blood tests [72, 73], advances in riskreducing lifestyle programs [3, 74-77] and progress on disease-modifying therapies [78-81].”
BackgroundKhoury, N., Pizzo, M. E., Discenza, C. B., Joy, D. A., Tatarakis, D., Todorov, M. I., Negwer, M., Ha, C., de Melo, G. L., Sarrafha, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57108-x · Cited by 85
“One example where more homogenous biodistribution has the potential to further improve ef fi cacy are for amyloid antibodies for the treatment of Alzheimer ’ s disease, some of which have been clinically approved in the last several years 37,38,70 .”
Hey, J. A., Kocis, P., Hort, J., Abushakra, S., Power, A., Vyhnálek, M., Yu, J. Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 71
“Furthermore, the brain MRI safety analyses from both phase III trials of tramiprosate revealed no cases of ARIA-E in subjects receiving the active drug.”
BackgroundInfluentialNeuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
“Aducanumab was shown to reduce plaque size and plaque burden and increased plaque clearance along with reduced cognitive decline in the AD mouse model Tg2576 as well as in Phase I clinical trials [258], suggesting that the observed effects of Aducanumab might be at least partially mediated by microglia.”
BackgroundUpregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease
Zhang, S., Zhao, J., Zhang, Y., Zhang, Y., Cai, F., Wang, L., & Song, W. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0508-x · Cited by 73
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054367 · Cited by 73
Zheng, Q., Song, B., Li, G., Cai, F., Wu, M., Zhao, Y., Jiang, L., Guo, T., Shen, M., Hou, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152170 · Cited by 73
“Dp(16)1Yey/+ DS model mice (36, 37) (referred to as Dp16 mice in this study; stock”
BackgroundVillemagne, V. L., Rowe, C. C., Barnham, K. J., Cherny, R., Woodward, M., Bozinosvski, S., Salvado, O., Bourgeat, P., Perez, K., Fowler, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.001 · Cited by 71
Button, E. B., Boyce, G. K., Wilkinson, A., Stukas, S., Hayat, A., Fan, J., Wadsworth, B. J., Robert, J., Martens, K. M., & Wellington, C. L. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0497-9 · Cited by 66
“Our current study demonstrates that the investigation of vascular-specific pathologies, including CAA and cerebrovascular astrogliosis, may be critical in future studies using HDL-based therapeutics to target AD pathology in general and vascular-specific amyloid pathologies including CAA, ARIA, and CAARI.”
BackgroundInfluentialDeng, R., Wu, H., Yan, W., & Mengdie, W. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113958 · Cited by 80
Toward deep MRI segmentation for Alzheimer’s disease detection
Helaly, H. A., Badawy, M., & Haikal, A. Y. (2021) · Neural Computing and Applications · doi:10.1007/s00521-021-06430-8 · Cited by 79
Engineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 91
“Aducanumab (BIIB037), a fully human IgG1 monoclonal antibody (mAb), was the first antibody therapy approved by the FDA for the AD treatment [39].”
InfluentialBrockmann, R., Nixon, J., Love, B. L., & Yunusa, I. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100467 · Cited by 65
Alzheimer’s Disease and ncRNAs
Maoz, R., Garfinkel, B. P., & Soreq, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_18 · Cited by 78
Snow, A. D., Castillo, G. M., Nguyen, B. P., Choi, P. Y., Cummings, J. A., Cam, J. A., Hu, Q., Lake, T. P., Pan, W., Kastin, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38645-0 · Cited by 82
Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Mendsaikhan, A., Tooyama, I., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8030230 · Cited by 72
Epelbaum, S., Burgos, N., Canney, M., Matthews, D., Houot, M., Santin, M. D., Desseaux, C., Bouchoux, G., Stroer, S., Martin, C., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00981-1 · Cited by 72
“However, such treatments’ effect on amyloid load and cognitive function are dosedependent [9], and only 0.”
Backgroundd’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 79
CADASIL from Bench to Bedside: Disease Models and Novel Therapeutic Approaches
Manini, A., & Pantoni, L. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02282-4 · Cited by 99
Iyaswamy, A., Wang, X., Krishnamoorthi, S., Kaliyamoorthy, V., Sreenivasmurthy, S. G., Durairajan, S. S. K., Song, J., Tong, B. C., Zhu, Z., Su, C.-F., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102280 · Cited by 78
Self-citationYu, H. J., Dickson, S. P., Wang, P., Chiu, M., Huang, C., Chang, C., Liu, H., Hendrix, S. B., Dodart, J., Verma, A. K., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104665 · Cited by 81
Liang, Y., Liu, C., Cheng, M., Geng, L., Li, J., Du, W., Song, M., Chen, N., Yeleen, T. A. N., Li, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14057 · Cited by 83
Ponezumab in mild‐to‐moderate Alzheimer's disease: Randomized phase II PET‐PIB study
Landen, J. W., Andreasen, N., Cronenberger, C. L., Schwartz, P. F., Börjesson‐Hanson, A., Östlund, H., Sattler, C. A., Binneman, B., & Bednar, M. M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.003 · Cited by 69
“Aducanumab, which has selectivity for fibrillary amyloid has demonstrated convincing phase II results in support of the amyloid hypothesis [28].”
BackgroundMann, A. P., Scodeller, P., Hussain, S., Braun, G. B., Mölder, T., Toome, K., Ambasudhan, R., Teesalu, T., Lipton, S. A., & Ruoslahti, E. I. (2017) · Nature Communications · doi:10.1038/s41467-017-01096-0 · Cited by 80
Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Cacabelos, R. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1457645 · Cited by 70
Yang, J., Hwang, I., Cha, M. G., Kim, H., Yim, D., Jeong, D. H., Lee, Y., & Kim, J. (2019) · Small · doi:10.1002/smll.201900613 · Cited by 71
Benchmarking machine learning models for late-onset alzheimer’s disease prediction from genomic data
De Velasco Oriol, J., Vallejo, E. E., Estrada, K., Taméz Peña, J. G., & Disease Neuroimaging Initiative, T. A. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3158-x · Cited by 71
“impact before the development of the disease [4].”
BackgroundAssociation of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011883 · Cited by 71
Ismail, R., Hansen, A. K., Parbo, P., Brændgaard, H., Gottrup, H., Brooks, D. J., & Borghammer, P. (2018) · International Journal of Alzheimer s Disease · doi:10.1155/2018/6852303 · Cited by 89
Immunotherapy in Parkinson’s disease: Current status and future directions
Chatterjee, D., & Kordower, J. H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104587 · Cited by 79
“BIIB054 was developed from human memory B-cell antibody libraries of healthy individuals (Weihofen et al., 2019), similar to screening methods used for selection of passive antibody constructs catered towards Aβ (Sevigny et al., 2016) and SOD1 (Maier et al., 2018).”
MethodDias, D., Portugal, C. C., Relvas, J. B., & Socodato, R. (2025) · Cells · doi:10.3390/cells14040243 · Cited by 78
“Several monoclonal antibodies targeting amyloid-beta (anti-A β ), including adu-canumab, lecanemab, have been shown to have sufficient ability during clinical trials to reduce amyloid-beta plaque levels and slow cognitive deterioration [37,49,92,93].”
Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 75
Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies
Zhao, J., Nussinov, R., & Ma, B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.801514 · Cited by 69
“For example, aducanumab (7, 8), a human monoclonal antibody, selectively targets aggregated A , reduces brain A in a dose- and time-dependent manner, and slows clinical decline (9).”
BackgroundYan, Q., Wang, W., Weng, J., Zhang, Z., Yin, L., Yang, Q., Guo, F., Wang, X., Chen, F., & Yang, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1797240 · Cited by 75
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Mattsson-Carlgren, N., Palmqvist, S., Blennow, K., & Hansson, O. (2020) · Nature Communications · doi:10.1038/s41467-020-19957-6 · Cited by 72
Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease
Yamamoto, Y., Kanayama, N., Nakayama, Y., & Matsushima, N. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030444 · Cited by 82
The Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives
Rosmus, D.-D., Lange, C., Ludwig, F., Ajami, B., & Wieghofer, P. (2022) · Biomedicines · doi:10.3390/biomedicines10040840 · Cited by 67
“However, clinical trials with drugs targeting the amyloid synthesis or deposition [118,119] have failed to ameliorate cognitive dysfunction, raising concerns as to whether the amyloid cascade theory adequately describes AD pathobiology [120].”
BackgroundPolymer Features in Crystallization
Hu, W. (2022) · Chinese Journal of Polymer Science · doi:10.1007/s10118-022-2710-8 · Cited by 72
Immunotherapies for Alzheimer’s Disease—A Review
Valiukas, Z., Ephraim, R., Tangalakis, K., Davidson, M., Apostolopoulos, V., & Feehan, J. (2022) · Vaccines · doi:10.3390/vaccines10091527 · Cited by 82
“The treatments resulted in ARIA– vasogenic oedema (ARIA-E), which was more common in participants that were APOE-ε4 positive [68,76], further demonstrating the gene’s implication in AD [37].”
BackgroundResultKaempferol as a therapeutic agent in Alzheimer’s disease: Evidence from preclinical studies
Dong, X., Zhou, S., & Nao, J. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101910 · Cited by 76
Formolo, D. A., Yu, J., Lin, K., Tsang, H. W. H., Ou, H., Kranz, G. S., & Yau, S. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00618-3 · Cited by 78
“has fostered the development of anti-amyloid agents [103–105], leading to the FDA approval of the monoclonal antibody Aducanumab [106] and, more recently, the Lecanemab [107], while other antibody-based interventions, such as the Gantenerumab [108], are likely to be approved soon [104, 105].”
BackgroundInfluentialBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 89
“Aducanumab and lecanemab received accelerated approved for the treatment of early AD based on changes in amyloid PET 38,195,202 .”
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 89
Marsh, S. E., Yeung, S. T., Torres, M., Lau, L., Davis, J. L., Monuki, E. S., Poon, W. W., & Blurton-Jones, M. M. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.019 · Cited by 71
“However, thus far these anti-amyloid efforts have failed to slow cognitive decline in late-stage clinical trials (Schenk et al., 2012), although whether earlier intervention can provide efficacy is currently being examined (Sevigny et al., 2016).”
BackgroundAn in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease
Jin, M., O’Nuallain, B., Hong, W., Boyd, J., Lagomarsino, V. N., O’Malley, T. T., Liu, W., Vanderburg, C. R., Frosch, M. P., Young-Pearse, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05068-w · Cited by 69
Gustavsson, T., Syvänen, S., O’Callaghan, P., & Sehlin, D. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00214-1 · Cited by 70
Zhang, M., He, P., & Bian, Z. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.685143 · Cited by 71
“The polypeptide is the main cause of neuronal degeneration and cell death in AD brains (Sevigny et al., 2016).”
BackgroundAlzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 75
Chiral Nanoparticles Force Neural Stem Cell Differentiation to Alleviate Alzheimer's Disease
Shi, B., Zhao, J., Xu, Z., Chen, C., Xu, L., Xu, C., Sun, M., & Kuang, H. (2022) · Advanced Science · doi:10.1002/advs.202202475 · Cited by 72
The shared role of cholesterol in neuronal and peripheral inflammation
Hansen, S. B., & Wang, H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108486 · Cited by 73
The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges
Zheng, H., Sun, H., Cai, Q., & Tai, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094969 · Cited by 79
Optimal Reference Region to Measure Longitudinal Amyloid-β Change with 18F-Florbetaben PET
Bullich, S., Villemagne, V. L., Catafau, A. M., Jovalekic, A., Koglin, N., Rowe, C. C., & De Santi, S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187351 · Cited by 66
“WCER has been used successfully to track amyloid changes in therapeutic clinical trials using 18F-florbetapir (3).”
MethodAlzheimer's disease and osteoporosis
Lo, R. Y., & Chen, Y. (2017) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_54_17 · Cited by 75
“Amyloid positron emission tomography (PET) showed that cerebral amyloid plaques were cleared after a series of injections of aducanumab for 12 months, along with stabilization of cognitive deterioration [46].”
BackgroundHameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 74
Alzheimer’s disease: where next for anti-amyloid therapies?
Hardy, J., & De Strooper, B. (2017) · Brain · doi:10.1093/brain/awx059 · Cited by 67
Lowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures
Knopman, D. S. (2019) · New England Journal of Medicine · doi:10.1056/nejme1903193 · Cited by 69
Potential Utility of Retinal Imaging for Alzheimer’s Disease: A Review
Liao, H., Zhu, Z., & Peng, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00188 · Cited by 74
“…prodromal or mild AD did not have enough power to detect clinical change, however, post hoc analysis suggested the reduction of Aβ burden in brain and a stabilization of cognitive decline based on Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores (Sevigny et al., 2016).”
MethodXu, M., Huang, H., Mo, X., Zhu, Y., Chen, X., Li, X., Peng, X., Xu, Z., Chen, L., Rong, S., et al. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000660 · Cited by 72
Role of Cognitive Frailty in Older Adults With Cardiovascular Disease
Ijaz, N., Jamil, Y., Brown, C. H., Krishnaswami, A., Orkaby, A. R., Stimmel, M. B., Gerstenblith, G., Nanna, M. G., & Damluji, A. A. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033594 · Cited by 74
Alkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
Immune Regulation of Antibody Access to Neuronal Tissues
Iwasaki, A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.004 · Cited by 73
“Moreover, in APP Tg mice, treatment with the mouse version of aducanumab, a murine IgG2a/κ chimeric analog, resulted in reduction of Aβ deposits, accompanied by an increased recruitment of microglia [11].”
Influentialde Matos, A. M., de Macedo, M. P., & Rauter, A. P. (2018) · Medicinal Research Reviews · doi:10.1002/med.21440 · Cited by 66
Xiang, C.-P., Han, J.-X., Li, X., Li, Y., Zhang, Y., Chen, L., Qu, Y., Hao, C., Li, H., Yang, C.-R., et al. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b01350 · Cited by 68
Takata, K., Amamiya, T., Mizoguchi, H., Kawanishi, S., Kuroda, E., Kitamura, R., Ito, A., Saito, Y., Tawa, M., Nagasawa, T., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.021 · Cited by 72
Grober, E. H., Veroff, A. E., & Lipton, R. B. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.12.004 · Cited by 80
“Spaghetti plots from the Baltimore Longitudinal Study of Aging (BLSA) an (AD): (A) BLSA free recall, (B) EAS free recall, (C) EAS total recall, (D) EAS s Mini Mental State Exam [5], Selective Reminding Test [6,7], the California Verbal Learning Test [8], and Logical Memory [9,10]; its effectiveness at detecting amnest…”
MethodChiao, P., Bedell, B. J., Avants, B., Zijdenbos, A. P., Grand'Maison, M., O’Neill, P., O’Gorman, J., Chen, T., & Koeppe, R. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209130 · Cited by 63
Self-citationDing, Y., Zhao, J., Zhang, X., Wang, S., Viola, K. L., Chow, F. E., Zhang, Y., Lippa, C., Klein, W. L., & Gong, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01140 · Cited by 65
“Here, we examined whether soluble oligomers of Aβ, which are formed in the early stages of AD, could inhibit Na/K-ATPase in vitro, and whether this inhibition could be prohibited by a polyclonal antiAβ antibody (4, 61, 62).”
BackgroundModulation of γ- and β-secretases as early prevention against Alzheimer's disease
Voytyuk, I., De Strooper, B., & Chávez-Gutiérrez, L. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.001 · Cited by 67
“In addition, Aβimmunotherapies like bapineuzemab and aducanemab tested in clinical trials focus on removing amyloid deposits (4, 5).”
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Lopes Alves, I., Collij, L. E., Altomare, D., Frisoni, G. B., Saint‐Aubert, L., Payoux, P., Kivipelto, M., Jessen, F., Drzezga, A., Leeuwis, A., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12069 · Cited by 67
Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing
Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 70
“Aducanumab is a monoclonal antibody that targets Aβ aggregations [159].”
BackgroundAlinsaif, S., & Lang, J. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104879 · Cited by 71
“Although a cure for AD does not exist, the drugs in a trial show that patients who are diagnosed early benefit the most [58].”
Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 70
“AD patients treated with aducanumab showed no cognitive improvement (Selkoe, 2019) despite the significant reduction of Aβ plaques in various brain regions (Sevigny et al., 2016).”
BackgroundThe complex pathway between amyloid β and cognition: implications for therapy
Jagust, W. J., Teunissen, C. E., & DeCarli, C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00128-x · Cited by 71
Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy
Liu, J., Yang, B., Ke, J., Li, W., & Suen, W.-C. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0406-x · Cited by 74
“The phase Ib clinical (NCT01397539 [56]) trial using aducanumab to treat patients with prodromal to mild AD showed a statistically significant reduction in cognitive decline [98].”
BackgroundRaikwar, S. P., Thangavel, R., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1068-y · Cited by 73
Zhang, H., Zhao, Y., Yu, M., Zhao, Z., Liu, P., Cheng, H., Ji, Y., Jin, Y., Sun, B., Zhou, J., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.008 · Cited by 69
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response
Pellerin, K., Rubino, S. J., Burns, J. C., Smith, B. A., McCarl, C.-A., Zhu, J., Jandreski, L., Cullen, P., Carlile, T. M., Li, A., et al. (2021) · Brain · doi:10.1093/brain/awab231 · Cited by 62
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
“Aducanumab (formerly BIIB037) is a humanized IgG1 mAb targeting amino acids 3 – 7 of the A β peptide, which can specifically bind soluble A β oligomers and insoluble A β fibrils (Sevigny et al., 2016).”
BackgroundPhage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication
Munke, A., Persson, J., Weiffert, T., Genst, E. D., Meisl, G., Arosio, P., Carnerup, A. M., Dobson, C. M., Vendruscolo, M., Knowles, T. P. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700407114 · Cited by 77
“Recent advances include the use of autoantibodies derived from elderly individuals who are cognitively normal, with some favorable indications for aggregate-specific antibody Aducanumab (19).”
BackgroundRestoring synaptic plasticity and memory in mouse models of Alzheimer’s disease by PKR inhibition
Hwang, K.-D., Bak, M. S., Kim, S. J., Rhee, S., & Lee, Y.-S. (2017) · Molecular Brain · doi:10.1186/s13041-017-0338-3 · Cited by 66
Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice
Leinenga, G., & Götz, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00055 · Cited by 65
“In addition, anti-Aβ vaccines that are currently in Frontiers in Neuroscience | www.frontiersin.org 4 February 2018 | Volume 12 | Article 55 clinical trials may pose the risk of microbleeds, so-called ARIA-H on magnetic resonance imaging (Sevigny et al., 2016).”
BackgroundQu, W., Yuan, B., Liu, J., Liu, Q., Zhang, X., Cui, R., Yang, W., & Li, B. (2021) · Cell Proliferation · doi:10.1111/cpr.12959 · Cited by 66
Abyadeh, M., Gupta, V., Gupta, V., Chitranshi, N., Wu, Y., Amirkhani, A., Meyfour, A., Sheriff, S., Shen, T., Dhiman, K., et al. (2021) · Aging and disease · doi:10.14336/ad.2021.0719 · Cited by 62
“In this study, anti-Aducanumab antibodies with minimal titers were observed only in 3% of Aducanumab treated patients, which had no clear impact on Aducanumab pharmacokinetics [44, 45].”
BackgroundRecent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review
Xing, H., Yue, S., Qin, R., Du, X., Wu, Y., Zhangsun, D., & Luo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083905 · Cited by 72
“…A β aggregation, including compounds such as ALZ-801 [66] and PBT2 [67]; and (4) mitigating the toxic e ff ects of A β aggregates, as represented by ALX-001 [68] and CT1812 [69]. of A β aggregates, as represented by ALX-001 [68] and CT1812 [69]. antibody that selectively targets aggregated A β [70].”
Lu, R., Wang, J., Tao, R. N., Wang, J., Zhu, T., Guo, W., Sun, Y., Li, H., Gao, Y., Zhang, W., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.136 · Cited by 68
The Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia
Folch, J., Ettcheto, M., Busquets, O., Sánchez-López, E., Castro-Torres, R., Verdaguer, E., Manzine, P., Poor, S., García, M., Olloquequi, J., et al. (2018) · Pharmaceuticals · doi:10.3390/ph11010011 · Cited by 63
“These results suggest that the amyloidogenic hypothesis may contribute to the development of LOAD exacerbating its consequences, possibly along with other factors such as metabolic alterations, glia activation, mitochondrial alteration and oxidative stress, among others [23].”
BackgroundSecondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 72
Yao, J., Sun, B., Institoris, A., Zhan, X., Guo, W., Song, Z., Liu, Y., Hiess, F., Boyce, A. K. J., Ni, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108169 · Cited by 65
“Hence, the dominating therapeutic anti-AD strategy has been reducing Aβ depositions (Demattos et al., 2012; Kennedy et al., 2016; Sevigny et al., 2016).”
BackgroundMonoclonal Antibodies as Neurological Therapeutics
Gklinos, P., Papadopoulou, M., Stanulovic, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 61
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Fan, L., Tzen, K., Chen, Y., Chen, T., Lai, Y., Yen, R., Huang, Y.-Y., Shiue, C., Yang, S., & Chiu, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00175 · Cited by 68
Self-citation
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.